Page 175 - 2020_02-Haematologica-web

HLA-matched unrelated or haploidentical donor
Table 1. Patients’, disease and transplant characteristics.
Variable
Number
Age, years
50 – 59 60 – 69 70 – 79
Sex, male/female
Performance score
90–100 ≤80
Not reported
HCT- comorbidity index 0–2
≥3
Not reported
Cytomegalovirus serostatus
Negative Positive
Not reported
Disease status
First complete remission Second complete remission
Cytogenetic risk
Favorable Intermediate Poor
Not reported
Conditioning regimen
Myeloablative
Busulfan/cyclophosphamide Busulfan/fludarabine
TBI + other agents
Reduced intensity
Busulfan/fludarabine Melphalan/fludarabine TBI/cyclophosphamide/fludarabine TBI + other agents
Graft type
Bone marrow Peripheral blood
Donor-recipient relationship/HLA-match Haploidentical sibling
Offspring
HLA match: A, B, C, DRB1
Donor age, median (range) Transplant period
2008 – 2011
2012 – 2015
Median follow up of survivors
months (range)
Haploidentical donor
192
85 (44%)
89 (46%)
18 (9%)
104 (54%)/88 (46%)
114 (59%) 67 (35%) 11 (6%)
108 (56%) 84 (44%) −
63 (33%) 128 (67%) 1 (<1%)
146 (76%) 46 (24%)
8 (4%) 148 (77%) 35 (18%) 1 (<1%)
25 (13%) 3 (1%) 19 (10%)
−
10 (5%) 124 (65%) 11 (6%)
132 (69%) 60 (31%)
48 (25%) 144 (75%) −
37 (16–69)
46 (24%) 146 (76%)
42 (12–97)
Unrelated donor P 631
0.7
266 (42%) 312 (49%) 53 (8%)
356 (56%)/275 (44%) 0.6
384 (61%) 241 (38%) 6 (<1%)
310 (49%) 317 (50%) 4 (<1%)
220 (35%) 405 (64%) 6 (<1%)
524 (83%) 107 (17%)
20 (3%) 425 (67%) 176 (28%) 10 (2%)
108 (17%) 171 (27%) −
234 (37%) 118 (18%) −
−
96 (15%) 535 (85%)
−
−
631 (100%) 27 (18–40)
216 (34%) 415 (66%)
47 (5–124)
<0.001
0.1
0.7
0.03
0.03
<0.001
<0.001
<0.001 0.007
HCT: hematopoietic cell transplant; TBI: total body irradiation.
haematologica | 2020; 105(2)
409